Eben Tessari Sells 85,271 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• COO Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals stock at an average price of $35.52, totaling over $3 million, which marked a 65.73% decrease in his ownership.
• Shares of Kiniksa Pharmaceuticals traded up 2.4%, reaching $36.57, while the company boasts a market cap of $2.71 billion and has a 52-week high of $36.74.
• Analysts have set a consensus price target of $41.17 for Kiniksa Pharmaceuticals, with multiple firms upgrading their ratings and price targets significantly in recent months.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.52, for a total value of $3,028,825.92. Following the sale, the chief operating officer directly owned 44,452 shares of the company's stock, valued at approximately $1,578,935.04. This trade represents a 65.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total value of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.72, for a total value of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.

Kiniksa Pharmaceuticals International Trading Up 2.4%

Shares of NASDAQ:KNSA traded up $0.86 on Monday, reaching $36.57. The company had a trading volume of 549,450 shares, compared to its average volume of 671,153. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $36.74. The firm's 50 day simple moving average is $30.95 and its 200-day simple moving average is $26.59. The firm has a market capitalization of $2.71 billion, a PE ratio of 914.48 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $31,000. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. US Bancorp DE acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth about $33,000. Finally, Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on KNSA. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Finally, Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.